Treats moderate acne vulgaris in females at least 15 years of age. ANDA 90524, held by Novast Labs Ltd. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 90524 (Tri-Linyah), held by Novast Labs Ltd, was first approved by FDA on May 30, 2012, with 3 approved supplements and 0 published complete response letters.
Tri-Nymyo is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. Tri-Nymyo is also indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Tri-Nymyo should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. 1.1 Oral Contraceptive Tri-Nymyo Tablets are indicated for use by females of reproductive potential to prevent pregnancy. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 30, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tri-Linyah0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Apr 29, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Feb 3, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 5, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 30, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters